Advertisement

Topics

Latest "NeoMatrix Therapeutics" News Stories

10:25 EST 17th November 2018 | BioPortfolio

Here are the most relevant search results for "NeoMatrix Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about NeoMatrix Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about NeoMatrix Therapeutics for you to read. Along with our medical data and news we also list NeoMatrix Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of NeoMatrix Therapeutics Companies for you to search.

Showing "NeoMatrix Therapeutics" News Articles 1–25 of 7,900+

Relevant

M&As this week: Nabriva Therapeutics, Sangamo Therapeutics, Ryboquin

Nabriva Therapeutics has completed the acquisition of Zavante Therapeutics for $97.5m. The acquisition will add the target company’s CONTEPO™ drug, which...Read More... The post M&As this week: Nabriva Therapeutics, Sangamo Therapeutics, Ryboquin appeared first on Drug Development Technology.


Q Therapeutics, ReproCELL form MAGiQ, a CNS diseases JV

Fellow cell therapy companies Q Therapeutics Inc. and ReproCELL Inc. formed a 50/50-owned CNS disease-focused joint venture, ...

HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics

The acquisition strengthens HiFiBiO Therapeutics’ strategic focus on identifying first-in-class targets for multiple immune cell types, as well as applying industry-leading technologies to develop diverse antibody therapeutics. Specific The post HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics appeared first on Pharma Business review.


Small-Cap Snapshot: Galectin Therapeutics flies after receiving a patent for treating pulmonary fibrosis

Aquinox Pharmaceuticals, Summit Therapeutics and Global Blood Therapeutics are also making news

Deals and M&As this week: Pliant Therapeutics, MolMed, Modus Therapeutics

Pliant Therapeutics has raised $62m through a series B financing round from Cowen Healthcare Investments. The funding round also included participation...Read More... The post Deals and M&As this week: Pliant Therapeutics, MolMed, Modus Therapeutics appeared first on Drug Development Technology.

Deals this week: Celsius Therapeutics, Xenikos, Nohla Therapeutics

Celsius Therapeutics has raised $65m in a series A financing round led by Third Rock Ventures with participation from Google Ventures,...Read More... The post Deals this week: Celsius Therapeutics, Xenikos, Nohla Therapeutics appeared first on Drug Development Technology.

iCo Therapeutics Announces Positive Clinical Outcome - Primary Endpoint Met in Phase 1 Oral Amphotericin B Study

Vancouver, British Columbia--(Newsfile Corp. - June 27, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., to...

Probably Relevant

iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials - Phase 1 Oral Amphotericin B

Vancouver, British Columbia--(Newsfile Corp. - July 16, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., to...

Deals this week: Impact Therapeutics, Sienna Biopharmaceuticals, Advanced Proteome Therapeutics

Impact Therapeutics has raised $30m through a series C financing round from Decheng Capital (Decheng). Existing investor Lilly Asian Ventures (LAV)...Read More... The post Deals this week: Impact Therapeutics, Sienna Biopharmaceuticals, Advanced Proteome Therapeutics appeared first on Drug Development Technology.

Dermatology start-up Hoth Therapeutics files for IPO

Hoth Therapeutics Inc. (technology that creates a topical agent from existing therapeutics to treat skin diseases) filed for ...

Nabriva Acquires Zavante Therapeutics and its Late-Stage Antibiotic

Shares of Nabriva Therapeutics are rising this morning after the company announced it acquired privately-held Zavante Therapeutics.

HiFiBio acquires H-Immune Therapeutics

HiFiBio Therapeutics acquired French biotech H-Immune Therapeutics, a privately held firm developing immuno-oncology therapie...

AdoRx raises $10m funding to discover new cancer therapeutics

UK-based AdoRx Therapeutics, which is focused on discovering new cancer therapeutics, has secured an initial $10m investment round financed by Epidarex Capital and CRT Pioneer Fund (CPF).

SMi Group announces the 10th Annual RNA Therapeutics Conference

20 - 21 February 2019, London, UK. Undoubtedly, the field of RNA therapeutics is currently undergoing a major expansion, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come.

Appointments: New CEO For Silence Therapeutics, Medical Heads Join Merck, Breath Therapeutics, Immusoft

David Solomon’s entrance as Silence Therapeutics’ new CEO leads this week’s new hires. While Ireland-based Malin shakes up its board...    

Carisma Therapeutics to expand its technology platform towards clinical development

Carisma Therapeutics Inc., formerly CARMA Therapeutics, a privately─held biotechnology company focused on the development of macrophage─based immunotherapeutics, announced the close of a $53 million Series A

Summit Therapeutics plc: Summit Therapeutics to Present at the Canaccord Genuity Growth Conference

Summit Therapeutics plc('Summit', or the 'Company')Summit Therapeutics to Present at the Canaccord Genuity Growth ConferenceOxford, UK, and Cambridge, MA, US, 6 August 2018 - Summit Therapeutics p...

PTC Therapeutics to commercialise Akcea’s two rare disease drugs

Ionis Pharmaceuticals affiliate Akcea Therapeutics has signed an agreement with biopharmaceutical company PTC Therapeutics for the commercialisation of its rare...Read More... The post PTC Therapeutics to commercialise Akcea’s two rare disease drugs appeared first on Pharmaceutical Technology.

Nasdaq Stockholm AB: Observationsnoteringen för Wilson Therapeutics AB uppdateras / The observation status for Wilson Therapeutics AB is updated (89/18)

Den 11 april 2018 observationsnoterades aktierna i Wilson Therapeutics AB ("Bolaget") med hänvisning till ett offentligt uppköpserbjudande från Alexion Pharmaceuticals Inc., genom dess dotterbolag ...

From Parkinson’s to asthma: opportunities for microbiome-based therapeutics

On September 5, speakers at the Microbiome Therapeutics US conference shed light on the future of microbiome therapeutics, which is...Read More... The post From Parkinson’s to asthma: opportunities for microbiome-based therapeutics appeared first on Pharmaceutical Technology.

Finch Therapeutics Names Ulrich Thienel Chief Medical Officer

Ulrich Theinel has been appointed chief medical officer of Finch Therapeutics. Before joining the Somerville, MA, microbiome therapeutics developer, Theinel held leadership positions at Novelion Therapeutics, Eleven Biotherapeutics, ImmunoGen, Domantis, and Transkaryotic Therapies. Finch is currently in mid-stage clinical studies testing its microbial therapy as a treatment for Clostridium diffici...

Abeona Therapeutics Inc.: Abeona Therapeutics ernennt Dr. João Siffert zum Leiter der Forschungs- und Entwicklungsabteilung sowie zum Chief Medical Officer

NEW YORK und CLEVELAND (USA), Oct. 18, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), ein führendes in der klinischen Erprobung tätiges Biopharma unternehmen, das sich auf die En...

Celsius Therapeutics Launches with $65M to Develop Precision Therapeutics for Autoimmune Disease & Cancer

Celsius Therapeutics, a company translating single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer, launched with a $65 million Series A financing led by Third Rock Ventures with participation from GV (formerly Google Ventures), Heritage Provider Network, Casdin Capital, Alexandria Venture Investments and other key investors. Celsius is charting a new course of...

Abeona Therapeutics Inc.: Abeona Therapeutics Appoints João Siffert, M.D. Head of Research and Development and Chief Medical Officer

NEW YORK and CLEVELAND, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene thera...

AdoRx raises $10m for new cancer therapeutics

UK-based drug discovery AdoRx Therapeutics has raised $10 million to fund its work on identifying new cancer therapeutics, in an investment round financed by Epidarex Capital and CRT Pioneer Fund.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks